
In October 2009, US FDA approved a new therapy for renal cell carcinoma. This was highlighted in Nature Reviews: Drug Discovery January, 2010 issue. Complete priscription information given on FDA web site.
"SAMSLESHANA" means synthesis

Nice video town hall discussion about future cancer research, little old one but good one on Future Cancer Research. Genentech focusing on anti-body conjugates for targeted specific delivery and pro apoptotic agents are undergoing clinical trails. In addition, Hedgehog signaling pathway also targeted to find cure for skin cancers.
Today an intersting news came out about a long term study of calorie restriction in higher animals (monkeys). Interstingly calorie restriction increased 10-20% life span. Autophagy (a kind of cell suicide) activated in both mTOR inhibition with Rapamycin and calorie restriction conditions, where some of our body cells (adipose tissue/fat) open up and used for generating energy to the body. In other way, if we stop this process by excess feeding, a kind of stress (ER stress) generated. This sustained stress leads to pancreas beta-cell failure and metabolic syndrome (diabetes, high blood pleassure, cardiovascular disease). High fat deposits also leads coronary heart disease. Calorie restriction and exercise helpful to improve this condition.The concept of selective inhibitors (Magic Bullets) one drug-one disease is no more an ideal in drug discovery. Knocking down one protein target is not enough to treat complex diseases like cancer. If we knock down multiple targets in a biological pathway of a disease with Designed Multiple Ligands (DMLs), we may expect improved efficacy. The trend in recent developments in anticancer drug discovery shifting towards a multi-target approach. One good example is recent wave of FDA approvals, "lapatinib" a dual EGFR and Her-2/neu kinase inhibitor. The other one “dasatanib” a multi kinase inhibitor and many more.